Robert Thomas Dechant - 31 Dec 2022 Form 3 Insider Report for IBEX Ltd (IBEX)

Role
Chief Executive Officer, Director
Signature
/s/ Lisa Lenstrohm, Attorney-in-Fact
Issuer symbol
IBEX
Transactions as of
31 Dec 2022
Net transactions value
$0
Form type
3
Filing time
30 Jun 2023, 16:12:20 UTC
Next filing
12 Nov 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding IBEX Common Shares 206,486 31 Dec 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding IBEX Stock Option (Right to Buy Common Shares) 31 Dec 2022 Common Shares 50,000 $12.75 Direct F2
holding IBEX Stock Option (Right to Buy Common Shares) 31 Dec 2022 Common Shares 45,027 $19.00 Direct F2
holding IBEX Stock Option (Right to Buy Common Shares) 31 Dec 2022 Common Shares 20,000 $19.85 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes (i) 932 restricted stock units ("RSUs") that vest on July 1, 2023 and (ii) 968 RSUs that vest on August 1, 2023, all subject to continued employment.
F2 The shares subject to this option are fully vested and exercisable.
F3 Performance stock units ("PSUs") granted on December 14, 2020. Each PSU represents a contingent right to receive one share of the Company's common shares. The PSUs vest upon the Company's common shares achieving a specified price per share over a 30 day period.

Remarks:

The Company determined that as of December 31, 2022, the Company no longer qualified as a foreign private issuer. Beginning July 1, 2023, the Reporting Person is subject to Section 16 of the Securities Exchange Act of 1934. Exhibit 24 - Power of Attorney